While CRISPR has grabbed the lion’s share of gene-editing headlines, Precision BioSciences has used its own gene-editing technology to quietly build a pipeline of products for both agriculture and human health. The Durham, NC company is now preparing to start testing a gene-edited cell therapy for cancer in humans and it has raised $110 million to support its efforts.
Precision Bio said Wednesday that it will apply the new capital, a Series B round of funding, toward clinical trials testing its cell therapy. The company also says it will ramp up pre-clinical work on a gene therapy program, and bring a… Read more »
UNDERWRITERS AND PARTNERS